Eurofins Scientific (ERFSF)

Thursday

5:30 PM

ThesisThe recent acquisition and new testing capabilities position Eurofins for accelerated growth, particularly in emerging markets and high-demand sectors.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$7.3B	$7.5B	$7.9B
Rev. Growth	+4.9%	+2.6%	+5.4%
EPS	$2.64	$3.93	$4.48
EPS Growth	+23.9%	+49.0%	+13.8%
P/E (fwd)	32.9×	22.1×	19.4×

★ Analysts see FY2027 revenue reaching $7.9B — +5.4% growth in a single year.

What’s Driving the Stock

01Recent acquisition of a leading environmental testing lab in Brazil, expected to increase revenue by 10% in the next fiscal year.
02Launch of a new rapid testing method for food safety that reduces turnaround time by 50%, enhancing competitive positioning.
03Increased demand for pharmaceutical testing services driven by rising R&D budgets in the biotech sector, projected to grow 15% YoY.
04Potential regulatory changes in the EU that could increase testing requirements for food safety, driving higher demand for services.
05Increased focus on food safety and quality assurance
06Growth in personalized medicine and pharmaceutical testing
07Regulatory changes impacting food and pharmaceutical testing requirements
08Expansion into emerging markets such as Asia-Pacific and Latin America

FY2025 Snapshot

Revenue: $7.3B
Rev. Growth: +4.9%
Gross Margin: 68.1%
Op. Margin: 11.2%
Net Margin: 6.5%
Net Income: $475M
NI Growth: +16.8%
EPS: $2.64
1Y Return: +16.9%

My Notes

"Our commitment to innovation and expansion is driving our growth strategy forward."
Moat: Eurofins' extensive laboratory network and established reputation provide a strong competitive moat that is difficult for new entrants…
growth - investors are likely attracted to Eurofins for its consistent revenue growth and expansion opportunities in the testing market.
Interest rates affect Eurofins primarily through the cost of financing for acquisitions and capital expenditures.
Watch on earnings: Food testing market growth rate, Pharmaceutical R&D spending trends, Regulatory changes in key markets.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $7.5B to $7.9B as recent acquisition of a leading environmental testing lab in brazil.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.